rethinkPeptides Search
Menu
Home / Research library
Study breakdown

Semaglutide shifts LDL and HDL subfractions toward less atherogenic profiles independent of weight or HbA1c changes

RPEP-138482025Tóth, László Imre; Harsányi, Adrienn; Csiha, Sára; Molnár, Ágnes; Lőrincz, Hajnalka; Nagy, Attila Csaba; Paragh, György; Harangi, Mariann; Sztanek, Ferenc
evidence
The takeaway

In a 52-week RCT of 34 obese T2DM patients, semaglutide shifted LDL toward larger particles and HDL toward more protective subfractions versus sitagliptin, with lipid subfraction changes independent of weight or HbA1c reduction.

Anti-atherogenic lipid remodeling

Semaglutide shifted lipoprotein particles toward less dangerous profiles independent of weight loss—a new cardiovascular protection mechanism beyond traditional lipid lowering

What the researchers found

Semaglutide vs sitagliptin (52 weeks): ↓BMI, WC, HbA1c, LDL-C, non-HDL-C. LDL subfractions: shifted to larger (less atherogenic). HDL subfractions: shifted to more protective. Multivariate: subfraction changes independent of BMI/HbA1c. Sitagliptin: modest HbA1c improvement only.

Why it matters

Lipoprotein subfraction profile is a better predictor of cardiovascular risk than total LDL. Semaglutide's ability to shift toward less atherogenic subfractions—independent of weight loss—reveals a direct anti-atherogenic mechanism.

How the study worked

52-week single-center RCT. 34 obese T2DM (18 semaglutide, 16 sitagliptin). 31 non-diabetic obese controls. Lipoprint gel electrophoresis for lipoprotein subfractions.

What this study cannot tell us

Small RCT (34 patients). Single center. Lipoprint methodology limitations. Sitagliptin is a relatively weak comparator. Long-term cardiovascular endpoint correlation unknown.

How to read the evidence

52-week RCT with advanced lipid testing. Small but well-designed.

When this study was published

Published in 2025.

The bigger picture

This adds a new mechanism to semaglutide's cardiovascular protection: direct lipoprotein particle remodeling. Shifting LDL toward larger particles reduces atherogenic penetration of vessel walls.

Questions still open

  • Does the subfraction shift correlate with reduced atherosclerosis on imaging?
  • Is this effect unique to semaglutide or shared by other GLP-1 drugs?
  • Could subfraction analysis guide GLP-1 drug dose optimization?

Common questions

Does semaglutide improve cholesterol quality, not just quantity?
Yes. This study showed semaglutide not only lowered total LDL but also shifted LDL particles toward larger, less dangerous sizes. Similarly, HDL shifted toward more protective subtypes. These quality improvements were independent of weight loss—suggesting a direct effect on how the body processes fats.
Why does particle size matter for cholesterol?
Small, dense LDL particles penetrate artery walls more easily and are more prone to oxidation—both driving atherosclerosis. Larger LDL particles are less atherogenic. By shifting LDL toward larger particles, semaglutide may reduce cardiovascular risk beyond what standard cholesterol numbers suggest.

Read the original research

Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study.

International journal of molecular sciences, 26(13)

View on PubMed ↗Publisher’s paper ↗

Citation

Tóth, László Imre; Harsányi, Adrienn; Csiha, Sára; Molnár, Ágnes; Lőrincz, Hajnalka; Nagy, Attila Csaba; Paragh, György; Harangi, Mariann; Sztanek, Ferenc. (2025). Semaglutide Improves Lipid Subfraction Profiles in Type 2 Diabetes: Insights from a One-Year Follow-Up Study.. International journal of molecular sciences, 26(13). https://doi.org/10.3390/ijms26135951